EDP 494

Drug Profile

EDP 494

Alternative Names: EDP-494

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 06 Jan 2017 Discontinued - Phase-I for Hepatitis C in USA
  • 11 Nov 2016 Adverse events and pharmacokinetics data from a phase I trial in Hepatitis C (In volunteers) presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 20 Jun 2016 Enanta Pharmaceuticals completes a clinical trial in Hepatitis C (In volunteers) in USA before June 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top